港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,777.994

-15.048-0.84%

漲家數：3

跌家數：5

平家數：- -

市盈率：- -

高：1,840.451

開：1,793.941

低：1,775.287

收：1,793.042

資料載入中...

復星醫藥(02196)：星盛新輝收到國家藥監局關於同意XS-03片的藥品臨牀試驗批准

【眾生藥業：控股子公司獲得一類創新藥RAY1225注射液III期臨牀試驗倫理批件】金融界2月27日消息，近日，眾生藥業控股子公司眾生睿創自主研發的一類創新多肽藥物RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有雙重激動活性，可調節人體代謝和控制血糖。本次III期臨牀試驗組長單位倫理批件的獲得，標誌着該試驗將全面啓動。該注射液獲得倫理批件對公司短期財務狀況和經營業績不構成重大影響，但臨牀試驗存在風險和不確定性，公司將按規定履行信息披露義務。

【眾生藥業：RAY1225注射液III期臨牀試驗倫理批件獲批】眾生藥業公告，控股子公司眾生睿創自主研發的RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗(REBUILDING-2)獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是眾生睿創研發的、具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有GLP-1受體和GIP受體雙重激動活性，可通過刺激胰島素分泌、延緩胃排空等機制調節人體代謝和控制血糖，有望用於降糖、減肥、代謝綜合徵等多種代謝性疾病的治療。

藥明康德2月27日現1筆大宗交易成交金額201.71萬元

新浪证券-红岸工作室

恆瑞醫藥(600276.SH)：注射用SHR-A2009、阿得貝利單抗注射液獲得藥物臨牀試驗批准

復星醫藥獲批XS-03片臨牀試驗

康龍化成2月27日現1筆大宗交易成交金額1116.8萬元

新浪证券-红岸工作室

【復星醫藥：控股子公司XS-03片相關治療方案獲臨牀試驗批准】金融界2月27日消息，復星醫藥控股子公司江蘇星盛新輝醫藥有限公司的XS-03片與FOLFOX或FOLFIRI和貝伐珠單抗聯合用於治療RAS突變轉移性結直腸癌的臨牀試驗獲批准。XS-03是自主研發的小分子口服PLK1抑制劑，在多種腫瘤模型中展現顯著藥效且臨牀安全性良好，現階段針對該方案累計研發投入約20萬元。全球範圍內尚無同靶點的小分子抑制劑單藥或聯合治療方案獲批上市。但該方案及XS-03尚需開展系列臨牀研究並經審批通過方可上市，新藥研發存在風險。

金斯瑞生物科技02月27日遭主力拋售1974萬元

阿斯利康(AZN.US)口服小分子療法3期臨牀試驗結果積極

金斯瑞生物科技盤中異動下午盤急速跳水5.01%報12.880港元

藥明生物再次通過日本PMDA GMP檢查累計通過42次全球藥品監管機構檢查

藥明康德盤中異動早盤股價大跌3.00%報61.400港元

艾美疫苗獲FDA批准開展mRNA疫苗臨牀試驗

昭衍新藥盤中異動早盤股價大漲5.37%

維亞生物盤中異動大幅拉昇5.04%報1.460港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1777.9938,"timestamp":1741576830143,"preClose":1793.0419,"halted":0,"volume":36260559,"delay":0,"changeRate":-0.008392,"change":-15.048096,"pbRate":2.65369,"amount":801701247,"amplitude":0.036343,"prevYearClose":1395.7731,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"turnoverRate":0.003196,"marketCap":378194653184,"floatMarketCap":165389814528,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1840.4508,"amplitude":0.036343,"preClose":1793.0419,"low":1775.2866,"pbRate":"2.65369","latestPrice":1777.9938,"volume":36260559,"delay":0,"open":1793.9412,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"sixtyDayClose":1409.843,"secType":"PLATE","market":"HK","turnoverRate":0.003196,"peRate":33.079805,"marketCap":378194653184,"floatMarketCap":165389814528,"timestamp":1741576830143,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":3,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514492874","title":"復星醫藥(02196)：星盛新輝收到國家藥監局關於同意XS-03片的藥品臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514492874","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514492874?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 18:42","pubTimestamp":1740652968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，该公司控股子公司江苏星盛新辉医药有限公司于近日收到国家药品监督管理局关于同意XS-03片与FOLFOX或FOLFIRI 和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。截至目前的研究显示，XS-03 在多种肿瘤模型中展现较为显著的抑制肿瘤生长的药效，且临床安全性良好。截至本公告日期，XS-03 单药用于治疗RAS突变晚期实体瘤于中国境内处于I期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","BK1191","BK1515","BK0060","BK0175","BK0239","BK1593","BK0012","02196","BK0196","BK0096","BK1141","BK1583","BK0028","BK0183","BK1576","BK0187","600196"],"gpt_icon":0},{"id":"2514798938","title":"【眾生藥業：控股子公司獲得一類創新藥RAY1225注射液III期臨牀試驗倫理批件】金融界2月27日消息，近日，眾生藥業控股子公司眾生睿創自主研發的一類創新多肽藥物RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有雙重激動活性，可調節人體代謝和控制血糖。本次III期臨牀試驗組長單位倫理批件的獲得，標誌着該試驗將全面啓動。該注射液獲得倫理批件對公司短期財務狀況和經營業績不構成重大影響，但臨牀試驗存在風險和不確定性，公司將按規定履行信息披露義務。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514798938","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514798938?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:56","pubTimestamp":1740650165,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，近日，众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。本次III期临床试验组长单位伦理批件的获得，标志着该试验将全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175648431102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1141","BK4134","BK4144","03347","BK1583","BK1161","BK1576","GLP","III","BK4590","BK0188","BK0239","159992","BK0077","06978","002317"],"gpt_icon":0},{"id":"2514879859","title":"【眾生藥業：RAY1225注射液III期臨牀試驗倫理批件獲批】眾生藥業公告，控股子公司眾生睿創自主研發的RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗(REBUILDING-2)獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是眾生睿創研發的、具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有GLP-1受體和GIP受體雙重激動活性，可通過刺激胰島素分泌、延緩胃排空等機制調節人體代謝和控制血糖，有望用於降糖、減肥、代謝綜合徵等多種代謝性疾病的治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879859","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514879859?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:55","pubTimestamp":1740650130,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创自主研发的RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性，可通过刺激胰岛素分泌、延缓胃排空等机制调节人体代谢和控制血糖，有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175548431160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK1141","GLP","BK0239","III","BK4134","BK1576","002317","BK0077","03347","BK4144","BK4590","BK1583"],"gpt_icon":0},{"id":"2514879090","title":"藥明康德2月27日現1筆大宗交易 成交金額201.71萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879090","media":"新浪证券-红岸工作室","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514879090?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:40","pubTimestamp":1740649200,"startTime":"0","endTime":"0","summary":"　　2月27日，药明康德收跌3.07%，收盘价为62.45元，发生1笔大宗交易，合计成交量3.23万股，成交金额201.71万元。　　第1笔成交价格为62.45元，成交3.23万股，成交金额201.71万元，溢价率为0.00%，买方营业部为华泰证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海分公司。　　进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为1.22亿元。该股近5个交易日累计下跌2.97%，主力资金合计净流出10.28亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-27/doc-inemxmap0862580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0708995583.HKD","LU1997245094.SGD","BK1583","LU2125910500.SGD","LU2488822045.USD","LU0456842615.SGD","LU2045819591.USD","LU0052750758.USD","LU0320764599.SGD","02359","LU1997245177.USD","LU2242644610.SGD","603259","BK1576","BK0216","LU1046422090.SGD","BK1141"],"gpt_icon":0},{"id":"2514873549","title":"恆瑞醫藥(600276.SH)：注射用SHR-A2009、阿得貝利單抗注射液獲得藥物臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514873549","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514873549?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:21","pubTimestamp":1740648081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。截至目前，阿得贝利单抗注射液相关项目累计研发投入约78,471万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","600276","BK1583","LU2148510915.USD","BK0196","LU1064131003.USD","BK0183","BK0060","LU0405327494.USD","BK0012","BK0028","LU0405327148.USD","LU1969619763.USD","LU1064130708.USD","BK0188","BK0239","BK1576","BK1141","LU2488822045.USD","03347","LU1328615791.USD"],"gpt_icon":0},{"id":"2514216820","title":"復星醫藥獲批XS-03片臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514216820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514216820?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:01","pubTimestamp":1740646881,"startTime":"0","endTime":"0","summary":"2月27日，复星医药发布公告，控股子公司星盛新辉近日获得国家药品监督管理局批准，进行XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验。XS-03为公司自主研发的小分子口服PLK1抑制剂，具有抑制肿瘤细胞增殖及促进肿瘤细胞凋亡的作用。公告指出，全球范围内尚无同靶点的小分子抑制剂获批上市，这为XS-03的临床试验提供了市场机会。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1576","BK1515","03347","600196","BK1141","BK1583","BK1593","02196"],"gpt_icon":0},{"id":"2514875396","title":"康龍化成2月27日現1筆大宗交易 成交金額1116.8萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514875396","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514875396?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:01","pubTimestamp":1740646860,"startTime":"0","endTime":"0","summary":"　　2月27日，康龙化成收跌0.57%，收盘价为28.10元，发生1笔大宗交易，合计成交量40万股，成交金额1116.8万元。　　第1笔成交价格为27.92元，成交40.00万股，成交金额1,116.80万元，溢价率为-0.64%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为2.07亿元。该股近5个交易日累计下跌1.44%，主力资金合计净流出6192.99万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-27/doc-inemxmap0845095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03759","BK0216","BK1141","BK1576","300759"],"gpt_icon":0},{"id":"2514891820","title":"【復星醫藥：控股子公司XS-03片相關治療方案獲臨牀試驗批准】金融界2月27日消息，復星醫藥控股子公司江蘇星盛新輝醫藥有限公司的XS-03片與FOLFOX或FOLFIRI和貝伐珠單抗聯合用於治療RAS突變轉移性結直腸癌的臨牀試驗獲批准。XS-03是自主研發的小分子口服PLK1抑制劑，在多種腫瘤模型中展現顯著藥效且臨牀安全性良好，現階段針對該方案累計研發投入約20萬元。全球範圍內尚無同靶點的小分子抑制劑單藥或聯合治療方案獲批上市。但該方案及XS-03尚需開展系列臨牀研究並經審批通過方可上市，新藥研發存在風險。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891820","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891820?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 16:54","pubTimestamp":1740646452,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27165448428408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0096","BK1576","BK1515","BK0028","BK0183","03347","BK1574","BK0196","BK0060","159938","02196","600196","BK1583","09939","BK0175","BK1161","BK1593","BK0012","BK0187","BK1191","BK0239","BK1141"],"gpt_icon":0},{"id":"2514733908","title":"金斯瑞生物科技02月27日遭主力拋售1974萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514733908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514733908?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 16:16","pubTimestamp":1740644186,"startTime":"0","endTime":"0","summary":"02月27日, 金斯瑞生物科技股价跌2.21%，报收13.26元，成交金额3.61亿元，换手率1.28%，振幅7.08%，量比1.01。金斯瑞生物科技今日主力资金净流出1974万元，上一交易日主力净流出150万元。该股近5个交易日上涨7.41%，主力资金累计净流出1211万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6464万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171056abdf0aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171056abdf0aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","01548","HK0000320264.USD","BK1583","HK0000306685.HKD","HK0000306701.USD","BK1141","HK0000320223.HKD"],"gpt_icon":0},{"id":"2514593844","title":"阿斯利康(AZN.US)口服小分子療法3期臨牀試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2514593844","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514593844?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 14:01","pubTimestamp":1740636060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月27日，阿斯利康宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期上显示出统计学显著且具有临床意义的改善。据了解，SERENA-6是首个采用循环肿瘤DNA检测，发现肿瘤内分泌耐药性的出现并在疾病进展前提示治疗转换的全球性3期临床试验。Camizestrant是一种效力强劲的新一代口服SERD及雌激素受体完全拮抗剂，目前正在3期试验中接受评估，用于治疗HR阳性乳腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","BK4007","BK4585","LU0889565916.HKD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","BK1141","BK4588","BK1576","BK4568","03347","LU2417539215.USD","AZN","BK1583"],"gpt_icon":0},{"id":"2514846073","title":"金斯瑞生物科技盤中異動 下午盤急速跳水5.01%報12.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846073?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 13:01","pubTimestamp":1740632476,"startTime":"0","endTime":"0","summary":"2025年02月27日下午盘13时01分，金斯瑞生物科技股票出现异动，股价快速下跌5.01%。截至发稿，该股报12.880港元/股，成交量1731.5万股，换手率0.81%，振幅6.49%。资金方面，该股资金流入6511.4万港元，流出1.25466亿港元。金斯瑞生物科技股票所在的生物技术行业中，整体跌幅为1.65%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227130117a255c486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227130117a255c486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000320223.HKD","HK0000306685.HKD","BK1576","HK0000306701.USD","01548","HK0000320264.USD","BK1583"],"gpt_icon":0},{"id":"2514849719","title":"藥明生物再次通過日本PMDA GMP檢查 累計通過42次全球藥品監管機構檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2514849719","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514849719?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 12:30","pubTimestamp":1740630600,"startTime":"0","endTime":"0","summary":"无锡2025年2月27日 /美通社/ --全球领先的合同研究、开发和生产服务公司药明生物宣布，公司无锡基地的生物药原液生产厂再次通过日本药品医疗器械综合机构GMP检查。公司以零缺陷通过此次涵盖设施质量体系及生产全流程的现场检查，彰显了其在满足全球监管要求方面的卓越能力。截至目前，药明生物已累计成功通过42次全球药品监管机构检查，并获得美国、欧洲、中国、新加坡、日本及加拿大等国家和地区药监部门颁发的97项生产许可证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4628886_ZH28886_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1794554557.SGD","LU0043850808.USD","LU0348825331.USD","LU1880383366.USD","LU1242518857.USD","LU0051755006.USD","BK1589","LU0516423091.SGD","LU0140636845.USD","LU0572944931.SGD","LU0417516902.SGD","LU0708995583.HKD","LU0516422952.EUR","LU0359201612.USD","ESG","LU1242518931.SGD","LU1720050803.USD","LU0039217434.USD","BK4121","LU0417516738.SGD","LU0823426308.USD","BK1141","SG9999002463.SGD","LU0856984785.SGD","LU0327786744.USD","LU0348735423.USD","LU0326950275.SGD","LU0823426480.USD","LU0516423174.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0320764599.SGD","LU0052750758.USD","LU0819121731.USD","LU1688375341.USD","02269","LU2039709279.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0307460666.USD","BK1610","LU0516422366.SGD","LU0456827905.SGD","LU0516422440.USD","BK1576","LU0456846285.SGD","WXXWY","BK1521","LU0181495838.USD"],"gpt_icon":1},{"id":"2514114718","title":"藥明康德盤中異動 早盤股價大跌3.00%報61.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514114718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514114718?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 10:20","pubTimestamp":1740622808,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘10时20分，药明康德股票出现波动，股价急速跳水3.00%。截至发稿，该股报61.400港元/股，成交量248.313万股，换手率0.64%，振幅4.66%。资金方面，该股资金流入5416.03万港元，流出7763.92万港元。最近的财报数据显示，该股实现营业收入307.19亿港元，净利润72.44亿港元，每股收益2.50港元，毛利123.07亿港元，市盈率15.03倍。药明康德股票所在的生物技术行业中，整体跌幅为0.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271020099631e4a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271020099631e4a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320764599.SGD","LU2125910500.SGD","LU1046422090.SGD","02359","LU2045819591.USD","LU2242644610.SGD","LU0708995583.HKD","BK1576","LU0052750758.USD","BK1583","BK1141"],"gpt_icon":0},{"id":"2514814553","title":"艾美疫苗獲FDA批准開展mRNA疫苗臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814553","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514814553?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 10:12","pubTimestamp":1740622362,"startTime":"0","endTime":"0","summary":"2月27日，艾美疫苗（06660）发布公告，宣布其mRNA呼吸道合胞病毒疫苗已获得美国食品和药品监督管理局（FDA）批准开展临床试验。这是公司首次获得FDA批准进行临床试验，标志着其国际化战略的重要进展。公告中提到，该疫苗在临床前动物试验中，特异性IgG抗体滴度、真病毒中和抗体效价以及特异性T细胞免疫均显著高于国际上市的对照疫苗，显示出其研发成果的竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331295532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06660","BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2514819415","title":"昭衍新藥盤中異動 早盤股價大漲5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819415?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 09:51","pubTimestamp":1740621062,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时51分，昭衍新药股票出现异动，股价急速拉升5.37%。截至发稿，该股报16.100港元/股，成交量108.034万股，换手率0.91%，振幅9.55%。资金方面，该股资金流入925.19万港元，流出552.206万港元。昭衍新药股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，北海康成-B、科济药业-B、创胜集团-B涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、永泰生物-B，振幅分别为58.68%、18.33%、16.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227095102a25592b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227095102a25592b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","06127"],"gpt_icon":0},{"id":"2514819453","title":"維亞生物盤中異動 大幅拉昇5.04%報1.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819453?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 09:47","pubTimestamp":1740620824,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时47分，维亚生物股票出现波动，股价急速上涨5.04%。截至发稿，该股报1.460港元/股，成交量35.8万股，换手率0.02%，振幅4.32%。资金方面，该股资金流入43.56万港元，流出5.179万港元。维亚生物股票所在的生物技术行业中，整体跌幅为0.87%。其相关个股中，北海康成-B、科笛-B、永泰生物-B涨幅较大，振幅较大的相关个股有北海康成-B、永泰生物-B、思路迪医药股份，振幅分别为58.68%、16.25%、15.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094704abde871a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094704abde871a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","01873"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":9,"totalSize":211}]}}